Reptile Yellow Fungus Disease: Nannizziopsis Diagnosis and Antifungal Protocols

PublishedJuly 10, 2026Reading time14 minExoticRx Editorial

Editorially reviewed against published veterinary references. Awaiting credentialed clinical reviewer — our editorial process.

Clinical relevance

"Yellow fungus disease" remains the clinical shorthand for a group of dermatomycoses caused by Nannizziopsis spp. and related onygenalean fungi in captive lizards. Now formally termed nannizziomycosis when associated with Nannizziopsis, it is among the most common and most lethal infectious dermatoses of pet inland bearded dragons (Pogona vitticeps), green iguanas, veiled and panther chameleons, tegus, and several monitor species. Superficial scale changes are easily mistaken for dysecdysis, dermatophytosis, or thermal burns, and empirical topicals or short-course azoles routinely fail as lesions progress to deep granulomatous dermatitis, osteomyelitis, and disseminated mycosis.

Pathogens are contagious between cohabiting lizards, persist in enclosures on porous substrate, and require multi-month systemic therapy. Outcomes depend on early biopsy, species-appropriate antifungal selection, and aggressive husbandry correction. Snake fungal disease (ophidiomycosis) caused by Ophidiomyces ophidiicola is taxonomically related but clinically distinct and is covered in a separate ExoticRx article.

Taxonomy and pathogen biology

Until 2013, reptile-associated reports were grouped under Chrysosporium anamorph of Nannizziopsis vriesii (CANV), based on a single 1980s isolate. Two phylogenetic studies (Sigler et al., J Clin Microbiol 2013; Stchigel et al., 2013) showed CANV was polyphyletic and reorganized the complex into three genera in the order Onygenales, with the proposed new family Nannizziopsiaceae:

• Nannizziopsis — at least nine species, primarily lizard pathogens (and rare human opportunists in immunocompromised patients). Clinically relevant species include:
  • N. guarroi — the dominant cause of yellow fungus disease in Pogona vitticeps and green iguanas (Iguana iguana).
  • N. dermatitidis — chameleons and other lizards.
  • N. barbatae — central bearded dragons; emerging in Australia.
  • N. chlamydospora, N. arthrosporioides, N. crocodili, and others — sporadic cases across geckos, agamids, teiids, and crocodilians.
  • N. vriesii sensu stricto — now recognized as a relatively uncommon pathogen, despite lending its name to the original CANV designation.
• Paranannizziopsis — four species infecting squamates and tuataras. P. australasiensis has been associated with skin lesions in tuataras, captive snakes, and free-ranging panther chameleons in Florida.
• Ophidiomyces ophidiicola — the cause of ophidiomycosis (snake fungal disease) in captive and wild snakes; not a primary lizard pathogen and addressed separately.

All members are keratinophilic: they invade the stratum corneum, grow well at reptilian body temperatures (25–35 °C), and produce keratinases driving the characteristic hyperkeratotic, dyskeratotic dermatitis. Most are considered primary pathogens — capable of infecting healthy hosts — but disease expression is amplified by suboptimal POTZ, inappropriate humidity, inadequate UVB, malnutrition, overcrowding, shipping stress, and concurrent disease. Transmission via direct contact and shared substrate is well documented, and asymptomatic skin carriage has been reported. A small number of Nannizziopsis species (N. obscura, N. hominis, N. infrequens) have caused systemic disease in immunocompromised humans; risk to immunocompetent staff is low, but standard barrier precautions are warranted.

Clinical signs and species predilection

The classic presentation is multifocal yellow to yellow-brown crusts overlying ventral and lateral scales, often beginning on the mandible, gular region, ventrum, or limbs. Affected scales become thickened and dyskeratotic; underlying skin is friable and ulcerates on debridement. Lesions enlarge centrifugally and progress over weeks to months. Hallmark features:

• Yellow, brown, or grey-brown crusts and hyperkeratotic plaques tightly adherent to underlying epidermis.
• Multifocal cutaneous nodules and granulomas; ulceration with serosanguinous to caseous exudate.
• Dyskeratotic regrowth at shed margins; failure to slough crusts during ecdysis.
• Digital, tail-tip, and rostral involvement is common; deep extension to bone (digital osteomyelitis, mandibular osteolysis) occurs in advanced cases.
• Systemic dissemination to liver, lung, and coelomic serosa is typically a late or perimortem finding, presenting as nonspecific lethargy, anorexia, and weight loss.

Species-specific patterns:

• Inland bearded dragons (Pogona vitticeps) — N. guarroi and N. barbatae cause the textbook yellow fungus disease; mortality is high if untreated.
• Green iguanas (Iguana iguana) — N. guarroi with nodular dermatitis along dorsal crest, dewlap, and limbs.
• Chameleons (veiled, panther, Parson's) — N. dermatitidis and Paranannizziopsis spp.; lesions on casque, gular, and limbs.
• Tegus, monitors, and other large lizards — sporadic Nannizziopsis dermatomycosis resembling lesions in bearded dragons.
• Geckos and agamids — case reports across several Nannizziopsis species.

Differentials include dysecdysis, thermal burns, traumatic abrasions with secondary bacterial infection (often Gram-negative), dermatophytosis (rare), saprophytic fungi (Aspergillus, Fusarium, Trichophyton), and neoplasia (squamous cell carcinoma in older bearded dragons).

Diagnostic workup

Definitive diagnosis requires both histopathology and molecular confirmation. Cytology and culture are useful adjuncts but neither is sufficient alone — saprophytic contaminants are commonly recovered from reptile skin, and Nannizziopsis spp. cannot be reliably distinguished morphologically.

Skin scraping and cytology. Diff-Quik or lactophenol cotton blue stains can demonstrate hyaline, septate, parallel-walled hyphae (3–5 µm) ± arthroconidia. Cytology supports the differential but cannot speciate; a negative result does not rule out infection.

Biopsy and histopathology. A 4–6 mm punch biopsy from the active margin, processed with H&E plus PAS or Gomori methenamine silver, is the diagnostic foundation. Characteristic findings: marked orthokeratotic and parakeratotic hyperkeratosis, epidermal hyperplasia with dyskeratosis, intralesional hyphae and arthroconidia in the stratum corneum and superficial dermis, and pyogranulomatous-to-granulomatous dermatitis. Submit fresh tissue in addition to formalin if culture and PCR are planned.

Fungal culture. Sabouraud dextrose agar (with and without cycloheximide) at 25–30 °C; growth typically in 7–14 days but may take up to 4 weeks. Colonies are white to pale yellow, suedelike, with abundant arthroconidia. Phenotypic species identification is unreliable; refer isolates to a mycology reference laboratory.

PCR and ITS sequencing. Sequencing of the internal transcribed spacer (ITS) region on biopsy tissue or culture isolate is the current diagnostic gold standard. Pan-fungal ITS primers with Sanger sequencing reliably distinguish Nannizziopsis species from saprophytic contaminants and other onygenalean pathogens. A Paranannizziopsis-specific real-time PCR (ITS2) is available at select reference laboratories. Some species share >97% ITS identity; results require interpretation by a clinician familiar with the genus.

Other diagnostics. CBC and biochemistry establish a hepatic baseline before azole therapy and help stage systemic involvement. Radiographs or CT are indicated for suspected digital, mandibular, or coelomic extension. Aerobic bacterial culture in parallel is recommended — secondary infection is common.

Antifungal therapy

Treatment is systemic, prolonged (typically 2–6 months), with topical care and husbandry correction. Robust PK data come almost exclusively from Pogona vitticeps; extrapolation to other species should be cautious and monitored where feasible.

Evidence labels: STRONG = controlled trial or PK study with documented efficacy; MODERATE = PK study, case series, or formulary consensus; ANECDOTAL = single case report or expert opinion.

Voriconazole is the current first-line systemic agent for N. guarroi in bearded dragons. Van Waeyenberghe et al. (Med Mycol 2010) compared oral voriconazole 10 mg/kg q24h with oral itraconazole in experimentally infected bearded dragons; voriconazole achieved plasma concentrations exceeding the MIC of CANV isolates and eliminated infection in 6 of 7 dragons (mean 47 days), with one death versus five of seven on itraconazole. Voriconazole's broader spectrum and superior CNS, ocular, and bone penetration favor deep-tissue lesions. Adverse effects at 10 mg/kg are uncommon but include reversible hepatic enzyme elevation, anorexia, and (by mammalian and avian extrapolation) visual disturbances. Baseline and periodic plasma chemistry are advisable. Compounding to a stable suspension is generally required for accurate small-patient dosing.

Itraconazole is no longer first line for nannizziomycosis in bearded dragons. The Van Waeyenberghe trial reported high mortality on itraconazole 5 mg/kg PO q24h, predominantly hepatotoxicity. Subsequent reviews (Mans & Kettler, J Fungi 2023; Mader's, 3rd ed.) caution specifically against itraconazole monotherapy in juvenile bearded dragons and Parson's chameleons due to variable bioavailability and species-specific hepatotoxicity. It remains a reasonable second-line option in tuataras with Paranannizziopsis and in some chelonian and crocodilian indications.

Terbinafine is an allylamine with strong keratin affinity and a favorable reptile safety profile. Hellebuyck et al. (AJVR 2022) reported single-dose oral PK in bearded dragons at 20 mg/kg PO: peak plasma 435 ± 338 ng/mL at ~13 h, terminal half-life 21.2 ± 12.4 h, and plasma above 30 ng/mL (the N. guarroi MIC range) for >24 h in all and >48 h in most animals. Recommended dose is 20 mg/kg PO q24h, with q48h plausibly adequate based on susceptibility data. Caron et al. (2022) documented successful resolution of N. guarroi infection in a bearded dragon with systemic terbinafine. Combination with voriconazole has been used in refractory cases without controlled comparative data. Nebulized and SC-implanted terbinafine has been described in cottonmouths (Kane et al., J Zoo Wildl Med 2017).

Topical antifungals are adjunctive, not standalone. Options include miconazole 1–2% cream q12–24h, terbinafine 1% cream q24h, and dilute F10 SC (1:250) as soak or spray. Clotrimazole and ketoconazole have weaker in vitro activity against Nannizziopsis spp.

F10 SC veterinary disinfectant (benzalkonium chloride and polyhexanide) at the 1:250 dilution has demonstrated in vitro activity against N. guarroi (Schmidt-Ukaj et al. 2024) and is widely used for adjunctive skin therapy and nebulization. Note that higher than label-recommended concentrations are required for environmental disinfection against N. guarroi — consult the Schmidt-Ukaj protocol rather than relying on label dilutions for enclosure decontamination.

Nebulized antifungals. Voriconazole nebulization (compounded 10 mg/mL, 10–15 min q12–24h) and terbinafine nebulization have been described for refractory or pulmonary involvement; data are sparse.

Therapeutic drug monitoring of plasma voriconazole is feasible at human reference laboratories and is reasonable in patients failing to respond after 4–6 weeks. Target trough is generally extrapolated from human medicine (1–5 µg/mL) in the absence of validated reptile targets.

Wound care and supportive treatment

Local management is integral to outcome.

• Sedation or general anesthesia is usually required for adequate debridement (alfaxalone IM or IV ± benzodiazepine, or isoflurane mask induction). Correct hypothermia and dehydration first.
• Gentle mechanical debridement of crusts and necrotic tissue with moistened gauze, blunt curette, or No. 15 blade. Avoid aggressive sharp debridement of viable epidermis.
• Topical lavage with dilute chlorhexidine 0.05% or F10 SC 1:250 after debridement, then topical antifungal (see table above).
• Systemic analgesia — meloxicam 0.2–0.5 mg/kg PO/SC q24h or tramadol 5–10 mg/kg PO q24–72h (species-dependent PK).
• Concurrent antibiotic coverage guided by aerobic culture; empirical Gram-negative coverage with ceftazidime 20 mg/kg SC/IM q72h is reasonable pending culture for acutely ulcerated lesions.
• Fluid and nutritional support. SC crystalloids (15–25 mL/kg/day) and assist feeding are commonly required; anorexia is both a presenting sign and an azole side effect.
• Bath protocol. Daily shallow lukewarm baths (10–15 min) aid hydration, ecdysis, and crust softening; F10 SC may be added at 1:250.

Recheck every 2–3 weeks during induction; consider repeat biopsy or PCR at 8–12 weeks if response is ambiguous.

Husbandry and biosecurity

Husbandry correction is not optional. Recurrence is common when patients return to the same environment.

• Quarantine. Minimum 90 days in a separate room with dedicated tools and PPE. Asymptomatic carriage has been documented; consider PCR screening of skin swabs at intake and exit in valuable or breeding collections.
• Enclosure disinfection. Empty the enclosure, discard porous substrate (coconut fiber, wood chips, sphagnum), wash with detergent, then disinfect with F10 SC at the off-label higher concentration shown to inhibit N. guarroi (Schmidt-Ukaj et al. 2024) or 1:10 dilute household bleach (~0.5% sodium hypochlorite) for ≥10 minutes. Rinse thoroughly. Replace porous decor (driftwood, cork bark).
• Environmental parameters. Verify and document species-appropriate POTZ, humidity, photoperiod, and UVB output (UV index meter; replace bulbs every 6–12 months).
• Cohabitation. Physically separate affected animals; treat multi-animal enclosures as exposed.
• Concurrent disease. Screen for and address parasitism, nutritional secondary hyperparathyroidism, dystocia, and other immunosuppressive conditions.
• PPE. Gloves and dedicated smocks for staff and clients; thorough hand hygiene between animals.

Prognosis and outcome

Prognosis is guarded. Outcomes track several variables:

• Stage at diagnosis. Superficial dermatitis caught at the crusting stage and treated with voriconazole or terbinafine plus husbandry correction has a fair-to-good prognosis; reported cure rates in bearded dragon case series approach 60–80%.
• Species and pathogen. N. guarroi in inland bearded dragons remains the highest-mortality scenario in companion practice.
• Depth of invasion. Digital osteomyelitis, mandibular involvement, or systemic dissemination carries a poor prognosis; digit or limb amputation may be required for source control.
• Owner compliance. Months-long therapy, daily medication, and environmental management — failure of compliance is among the most common reasons for relapse.
• Recurrence. Documented after apparent cure, particularly when the original enclosure is reused or subclinical cohabitants are not screened. Monthly skin examination for 6–12 months post-treatment is reasonable.

Counsel owners at presentation that treatment cost commonly reaches several hundred to low thousands of dollars; euthanasia is appropriate in advanced systemic disease or refractory progression after 8–12 weeks of correct therapy.

When to refer

Referral to a board-certified reptile or zoological medicine specialist (ACZM, ECZM-Herpetology) is appropriate in any of the following:

• Lesions involving bone, joints, or the coelomic cavity, or radiographic evidence of digital or mandibular osteomyelitis.
• Lack of clinical response after 8 weeks of correctly dosed first-line therapy with documented compliance.
• Patients requiring digit, tail, or limb amputation, or extensive surgical debridement.
• Need for therapeutic drug monitoring, advanced imaging (CT, MRI), or interventional bronchoscopy for pulmonary involvement.
• Outbreak in a multi-animal collection or breeding facility — referral or consultation also enables population-level diagnostic and biosecurity planning.
• Owner request for a second opinion, particularly before euthanasia in advanced cases.

Suspected zoonotic exposure in immunocompromised household members should be referred to human infectious disease — Nannizziopsis spp. have caused systemic disease in immunocompromised humans.

Key references

• Sigler L, Hambleton S, Paré JA. Molecular characterization of reptile pathogens currently known as members of the Chrysosporium anamorph of Nannizziopsis vriesii complex and relationship with some human-associated isolates. J Clin Microbiol. 2013;51(10):3338–3357.
• Stchigel AM, Sutton DA, Cano-Lira JF, et al. Phylogeny of chrysosporia infecting reptiles: proposal of the new family Nannizziopsiaceae and five new species. Persoonia. 2013;31:86–100.
• Paré JA, Sigler L. An overview of reptile fungal pathogens in the genera Nannizziopsis, Paranannizziopsis, and Ophidiomyces. J Herpetol Med Surg. 2016;26(1–2):46–53.
• Van Waeyenberghe L, Baert K, Pasmans F, et al. Voriconazole, a safe alternative for treating infections caused by the Chrysosporium anamorph of Nannizziopsis vriesii in bearded dragons (Pogona vitticeps). Med Mycol. 2010;48(6):880–885.
• Hellebuyck T, Schoemaker NJ, et al. Single-dose pharmacokinetics of orally administered terbinafine in bearded dragons (Pogona vitticeps) and the antifungal susceptibility patterns of Nannizziopsis guarroi. Am J Vet Res. 2022;83(3):ajvr.21.02.0023.
• Caron A, et al. Successful treatment of Nannizziopsis guarroi infection using systemic terbinafine in a central bearded dragon (Pogona vitticeps). J Herpetol Med Surg. 2022.
• Schmidt-Ukaj S, et al. Benzalkonium chloride and polyhexanide disinfectant (F10 SC) requires off-label use for environmental disinfection to be effective against Nannizziopsis guarroi. J Exot Pet Med. 2024.
• Kane LP, Allender MC, Archer G, et al. Pharmacokinetics of nebulized and subcutaneously implanted terbinafine in cottonmouths (Agkistrodon piscivorus). J Zoo Wildl Med. 2017.
• Mans C, Kettler N. A critical review on the dosing and safety of antifungals used in exotic avian and reptile species. J Fungi (Basel). 2023;9(8):810.
• Mader DR, Divers SJ, Stahl SJ, eds. Mader's Reptile and Amphibian Medicine and Surgery. 3rd ed. Elsevier; 2019. (See chapters on integumentary disease and infectious dermatoses.)
• Carpenter JW, Marion CJ, eds. Carpenter's Exotic Animal Formulary. 6th ed. Elsevier; 2023. (Reptile antifungal section.)
• Allender MC, et al. TaqMan real-time PCR for detection of Ophidiomyces ophidiicola, the fungus associated with snake fungal disease. BMC Vet Res. 2015. (For differential diagnosis with snake fungal disease.)

Disclaimer: This article is intended as a clinical reference for licensed veterinary professionals. Dose ranges reflect published literature current at the time of writing and should be adapted to individual patient factors, jurisdiction, and current product availability. Off-label use of human antifungal pharmaceuticals is common in reptile medicine; ensure compliance with local regulations and informed client consent. ExoticRx editorial content does not replace consultation with a board-certified specialist when clinically indicated. Information is provided "as-is" without warranty; verify all dosing against primary sources before administration.